NEWS
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
NKGen Biotech (Nasdaq: NKGN) will present new biomarker data on its SNK01 therapy for Alzheimer's disease at the 2024 Alzheimer's Association International Conference.
The poster presentation will showcase SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant as α-synuclein correlates with worse cognitive function.
The presentation, titled 'Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF α-synuclein and in cognitive function,' will be held on July 30, 2024.
This data adds to previously disclosed Phase 1 results showing SNK01's positive effects on amyloid, tau, and neuroinflammation biomarkers in Alzheimer's patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2310Followers
105Following
24KVisitors
Follow